Prediction and Prevention of Type 1 Diabetes: Progress, Problems, and Prospects

Type 1 diabetes mellitus (T1D) arises from selective immunologically mediated destruction of the insulin‐producing β ‐cells in the pancreatic islets of Langerhans with consequent insulin deficiency. 1 , 2 This occurs in genetically susceptible individuals and is a cellular‐mediated process, presumably a specific reaction to one or more β ‐cell proteins (autoantigens), although probably initiated by some environmental factor(s). There is consequent progressive impairment of β ‐cell function and decline in β ‐cell mass. A secondary humoral immune response is characterized by the appearance of autoantibodies that serve as markers of the immune damage to β ‐cells. 3 , 4 , 5 This insidious T1D disease process evolves over a period of years. 6 The decline in β ‐cell function and mass is evidenced metabolically by loss of first‐phase insulin response to an intravenous glucose challenge, 7 , 8 and later by the appearance of impairment in glycemic regulation, manifested as dysglycemia—usually as impaired glucose tolerance, but occasionally as impaired fasting glucose. 9 Ultimately, the clinical syndrome of T1D becomes evident when the majority of β ‐cells have been destroyed and frank hyperglycemia supervenes. Given this sequence of events, for which it is possible to envision intervention to interdict the process, it is not surprising that much research effort has been expended to identify individuals at risk of the disease. Clinical Pharmacology & Therapeutics (2007) 81 , 768–771. doi: 10.1038/sj.clpt.6100179 ; published online 28 March 2007